Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly insulin icodec versus once-daily insulin degludec in adults with type 1 diabetes
NL-OMON52258Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin icodec in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to week 26. Started Jul 2021; status: active, not recruiting.
02
Drugs
insulin icodec
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON52258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52258.